Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Taro Clindamycin Gel vs RLD in Acne Vulgaris
NCT04134273Phase 1Completed
- Start
- Mar 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of clindamycin in acne vulgaris (3 arms). Primary endpoint: Demonstration of Bioequivalence at Week 12. Started Mar 2019; status: completed.
02
Drugs
clindamycin
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT04134273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04134273.